Nilotinib vs imatinib in ph+CML: 24-month data from phase 3 ENESTnd trial

8em; margin-top: 0.5em; color: black; line-height: 1.25em; font-family: 'Trebuchet MS', Verdana, sans-serif; background-color: rgb(255, 255, 255); ">Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Background: Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase after a minimum follow-up of 12 months. We present data from the Evaluating Nilotinib Efficacy and Safety in clinical Trials—newly diagnosed patients (ENESTnd) study after a minimum follow-up of 24 months.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70201-7/abstract